MRSN

1.39

0.71% -0.01

Dopo l'orario di chiusura: 1.45 0.06 +4.32%

Mersana Therapeutics Inc (MRSN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.40

Aprire:

$1.42

Volume 24 ore:

2.63M

Relative Volume:

2.20

Capitalizzazione di mercato:

$171.71M

Reddito:

$36.86M

Utile/perdita netta:

$-171.67M

Rapporto P/E:

-0.9267

EPS:

-1.5

Flusso di cassa netto:

$-171.05M

1 W Prestazione:

-7.33%

1M Prestazione:

-41.35%

6M Prestazione:

-24.46%

1 anno Prestazione:

-35.65%

Intervallo 1D:

$1.37

$1.455

Intervallo di 1 settimana:

$1.35

$1.515

Portata 52W:

$1.22

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Nome

Mersana Therapeutics Inc

Settore

Healthcare (1174)

Industria

Biotechnology (669)

Telefono

617-498-0020

Indirizzo

840 MEMORIAL DRIVE, CAMBRIDGE

Dipendente

123

Cinguettio

@MersanaADC

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

MRSN's Discussions on Twitter

Confronta MRSN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MRSN Mersana Therapeutics Inc	1.39	171.71M	36.86M	-171.67M	-171.05M	-1.50
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-15	Ripresa	Citigroup	Buy
2024-03-19	Aggiornamento	JP Morgan	Underweight → Neutral
2024-02-29	Aggiornamento	BTIG Research	Neutral → Buy
2024-02-29	Aggiornamento	Guggenheim	Neutral → Buy
2024-02-29	Aggiornamento	Wedbush	Neutral → Outperform
2023-12-04	Aggiornamento	Citigroup	Neutral → Buy
2023-07-28	Downgrade	Robert W. Baird	Outperform → Neutral
2023-07-27	Downgrade	BTIG Research	Buy → Neutral
2023-07-27	Downgrade	Citigroup	Buy → Neutral
2023-07-27	Downgrade	Guggenheim	Buy → Neutral
2023-07-27	Downgrade	JP Morgan	Neutral → Underweight
2023-07-27	Downgrade	Truist	Buy → Hold
2023-07-27	Downgrade	Wedbush	Outperform → Neutral
2023-06-16	Downgrade	JP Morgan	Overweight → Neutral
2023-06-15	Iniziato	Guggenheim	Buy
2023-03-16	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-20	Iniziato	Citigroup	Buy
2022-11-21	Iniziato	Truist	Buy
2021-10-15	Ripresa	BTIG Research	Buy
2021-08-30	Iniziato	H.C. Wainwright	Buy
2021-03-31	Iniziato	Credit Suisse	Neutral
2020-12-03	Iniziato	Stifel	Buy
2020-09-29	Ripresa	JP Morgan	Neutral
2020-04-29	Iniziato	BTIG Research	Buy
2020-01-21	Reiterato	H.C. Wainwright	Buy
2019-03-11	Downgrade	JP Morgan	Neutral → Underweight
2018-11-14	Aggiornamento	Leerink Partners	Mkt Perform → Outperform
2018-05-08	Iniziato	Robert W. Baird	Outperform
2018-03-19	Downgrade	JP Morgan	Overweight → Neutral

Mostra tutto

Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie

Dec 31, 2024

Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 31, 2024

Dec 30, 2024

State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 30, 2024

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Dec 28, 2024

Dec 19, 2024

Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 19, 2024

Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha

Dec 19, 2024

Dec 15, 2024

BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 15, 2024

Dec 13, 2024

XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 13, 2024

Dec 08, 2024

Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 08, 2024

Dec 06, 2024

Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World

Dec 06, 2024

Dec 03, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 03, 2024

Dec 01, 2024

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Dec 01, 2024

Nov 28, 2024

Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Nov 28, 2024

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024